Intellia Therapeutics Price to Sales Ratio 2015-2021 | NTLA

Historical PS ratio values for Intellia Therapeutics (NTLA) over the last 10 years. The current P/S ratio for Intellia Therapeutics as of January 19, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Intellia Therapeutics P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-01-20 82.62 202.72
2021-09-30 134.15 $0.41 329.16
2021-06-30 161.91 $0.69 235.33
2021-03-31 80.26 $0.90 89.51
2020-12-31 54.40 $1.06 51.49
2020-09-30 19.88 $1.17 16.99
2020-06-30 21.02 $1.01 20.80
2020-03-31 12.23 $0.95 12.89
2019-12-31 14.67 $0.92 15.89
2019-09-30 13.35 $0.87 15.26
2019-06-30 16.37 $0.83 19.77
2019-03-31 17.08 $0.76 22.34
2018-12-31 13.65 $0.71 19.19
2018-09-30 28.62 $0.71 40.10
2018-06-30 27.36 $0.75 36.48
2018-03-31 21.09 $0.74 28.49
2017-12-31 19.22 $0.74 25.92
2017-09-30 24.85 $0.81 30.69
2017-06-30 16.00 $0.74 21.52
2017-03-31 14.09 $0.79 17.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.149B $0.058B
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.655B 9.08
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.351B 19.22
Biohaven Pharmaceutical Holding (BHVN) United States $7.535B 0.00
Emergent Biosolutions (EBS) United States $2.453B 8.82
Arcus Biosciences (RCUS) United States $2.353B 0.00
Myovant Sciences (MYOV) United Kingdom $1.344B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.156B 0.00
Zymeworks (ZYME) Canada $0.627B 0.00
Ambrx Biopharma (AMAM) United States $0.207B 0.00
SQZ Biotechnologies (SQZ) United States $0.207B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81